{"id":193,"date":"2015-01-15T16:23:10","date_gmt":"2015-01-15T16:23:10","guid":{"rendered":"https:\/\/wwwtest.pharmacy.wisc.edu\/faculty\/wenthur-lab\/?p=193"},"modified":"2025-06-13T16:24:47","modified_gmt":"2025-06-13T16:24:47","slug":"metabotropic-glutamate-receptor-3-activation-is-required-for-long-term-depression-in-medial-prefrontal-cortex-and-fear-extinction","status":"publish","type":"post","link":"https:\/\/pharmacy.wisc.edu\/faculty\/wenthur-lab\/2015\/01\/15\/metabotropic-glutamate-receptor-3-activation-is-required-for-long-term-depression-in-medial-prefrontal-cortex-and-fear-extinction\/","title":{"rendered":"Metabotropic glutamate receptor 3 activation is required for long-term depression in medial prefrontal cortex and fear extinction"},"content":{"rendered":"

Abstract<\/h2>\r\n

Clinical studies have revealed that genetic variations in metabotropic glutamate receptor 3 (mGlu3<\/sub>) affect performance on cognitive tasks dependent upon the prefrontal cortex (PFC) and may be linked to psychiatric conditions such as schizophrenia, bipolar disorder, and addiction. We have performed a series of studies aimed at understanding how mGlu3<\/sub>\u00a0influences PFC function and cognitive behaviors. In the present study, we found that activation of mGlu3<\/sub>\u00a0can induce long-term depression in the mouse medial PFC (mPFC) in vitro. Furthermore, in vivo administration of a selective mGlu3<\/sub>\u00a0negative allosteric modulator impaired learning in the mPFC-dependent fear extinction task. The results of these studies implicate mGlu3<\/sub>\u00a0as a major regulator of PFC function and cognition. Additionally, potentiators of mGlu3<\/sub>\u00a0may be useful in alleviating prefrontal impairments associated with several CNS disorders.<\/p>\r\n\r\n

Funding Source<\/h2>\r\n
\r\n\r\nThis work was supported by a grant from the National Institute of Neurological Disease and Stroke (NS031373) (to P.J.C.), a postdoctoral fellowship from the Pharmaceutical Research and Manufacturers of America (PhRMA) Foundation (to A.G.W.), and a National Institutes of Health predoctoral Training Grant (T32 GM007628) (to C.J.W.).\r\n

Cited by<\/h2>\r\nThis article is cited by 51 publications\r\n
    \r\n \t
  1. \r\n
    Dogra, S., Putnam, J., & Conn, P. J. (2022). Metabotropic glutamate receptor 3 as a potential therapeutic target for psychiatric and neurological disorders.\u00a0Pharmacology, biochemistry, and behavior<\/i>,\u00a0221<\/i>, 173493.\u00a0https:\/\/doi.org\/10.1016\/j.pbb.2022.173493<\/a><\/div><\/li>\r\n \t
  2. \r\n
    Veselinovi\u0107, T., & Neuner, I. (2022). Progress and Pitfalls in Developing Agents to Treat Neurocognitive Deficits Associated with Schizophrenia.\u00a0CNS drugs<\/i>, 10.1007\/s40263-022-00935-z. Advance online publication.\u00a0https:\/\/doi.org\/10.1007\/s40263-022-00935-z<\/a><\/div><\/li>\r\n \t
  3. \r\n
    Luessen, D. J., & Conn, P. J. (2022). Allosteric Modulators of Metabotropic Glutamate Receptors as Novel Therapeutics for Neuropsychiatric Disease.\u00a0Pharmacological reviews<\/i>,\u00a074<\/i>(3), 630\u2013661.\u00a0https:\/\/doi.org\/10.1124\/pharmrev.121.000540<\/a><\/div><\/li>\r\n \t
  4. \r\n
    Vermudez, S., Buch, A., Weiss, K., Gogliotti, R. G., & Niswender, C. M. (2022). Exploration of group II metabotropic glutamate receptor modulation in mouse models of Rett syndrome and MECP2 Duplication syndrome.\u00a0Neuropharmacology<\/i>,\u00a0209<\/i>, 109022.\u00a0https:\/\/doi.org\/10.1016\/j.neuropharm.2022.109022<\/a><\/div><\/li>\r\n \t
  5. \r\n
    Dogra, S., & Conn, P. J. (2022). Metabotropic Glutamate Receptors As Emerging Targets for the Treatment of Schizophrenia.\u00a0Molecular pharmacology<\/i>,\u00a0101<\/i>(5), 275\u2013285.\u00a0https:\/\/doi.org\/10.1124\/molpharm.121.000460<\/a><\/div><\/li>\r\n \t
  6. \r\n
    Hall, J., & Bray, N. J. (2022). Schizophrenia Genomics: Convergence on Synaptic Development, Adult Synaptic Plasticity, or Both?.\u00a0Biological psychiatry<\/i>,\u00a091<\/i>(8), 709\u2013717.\u00a0https:\/\/doi.org\/10.1016\/j.biopsych.2021.10.018<\/a><\/div><\/li>\r\n \t
  7. \r\n
    Tyler, R. E., Bluitt, M. N., Engers, J. L., Lindsley, C. W., & Besheer, J. (2022). The effects of predator odor (TMT) exposure and mGlu3 NAM pretreatment on behavioral and NMDA receptor adaptations in the brain.\u00a0Neuropharmacology<\/i>,\u00a0207<\/i>, 108943.\u00a0https:\/\/doi.org\/10.1016\/j.neuropharm.2022.108943<\/a><\/div><\/li>\r\n \t
  8. \r\n
    Dogra, S., & Conn, P. J. (2021). Targeting metabotropic glutamate receptors for the treatment of depression and other stress-related disorders.\u00a0Neuropharmacology<\/i>,\u00a0196<\/i>, 108687.\u00a0https:\/\/doi.org\/10.1016\/j.neuropharm.2021.108687<\/a><\/div><\/li>\r\n \t
  9. \r\n
    Dogra, S., Stansley, B. J., Xiang, Z., Qian, W., Gogliotti, R. G., Nicoletti, F., Lindsley, C. W., Niswender, C. M., Joffe, M. E., & Conn, P. J. (2021). Activating mGlu3 Metabotropic Glutamate Receptors Rescues Schizophrenia-like Cognitive Deficits Through Metaplastic Adaptations Within the Hippocampus.\u00a0Biological psychiatry<\/i>,\u00a090<\/i>(6), 385\u2013398.\u00a0https:\/\/doi.org\/10.1016\/j.biopsych.2021.02.970<\/a><\/div><\/li>\r\n \t
  10. \r\n
    Ruan, H., & Yao, W. D. (2021). Loss of mGluR1-LTD following cocaine exposure accumulates Ca2+-permeable AMPA receptors and facilitates synaptic potentiation in the prefrontal cortex.\u00a0Journal of neurogenetics<\/i>,\u00a035<\/i>(4), 358\u2013369.\u00a0https:\/\/doi.org\/10.1080\/01677063.2021.1931180<\/a><\/div><\/li>\r\n \t
  11. \r\n
    Banks, M. I., Zahid, Z., Jones, N. T., Sultan, Z. W., & Wenthur, C. J. (2021). Catalysts for change: the cellular neurobiology of psychedelics.\u00a0Molecular biology of the cell<\/i>,\u00a032<\/i>(12), 1135\u20131144.\u00a0https:\/\/doi.org\/10.1091\/mbc.E20-05-0340<\/a><\/div><\/li>\r\n \t
  12. \r\n
    Xiang, Z., Lv, X., Lin, X., O’Brien, D. E., Altman, M. K., Lindsley, C. W., Javitch, J. A., Niswender, C. M., & Conn, P. J. (2021). Input-specific regulation of glutamatergic synaptic transmission in the medial prefrontal cortex by mGlu2\/mGlu4 receptor heterodimers.\u00a0Science signaling<\/i>,\u00a014<\/i>(677), eabd2319.\u00a0https:\/\/doi.org\/10.1126\/scisignal.abd2319<\/a><\/div><\/li>\r\n \t
  13. \r\n
    Joffe, M. E., Santiago, C. I., Oliver, K. H., Maksymetz, J., Harris, N. A., Engers, J. L., Lindsley, C. W., Winder, D. G., & Conn, P. J. (2020). mGlu2 and mGlu3 Negative Allosteric Modulators Divergently Enhance Thalamocortical Transmission and Exert Rapid Antidepressant-like Effects.\u00a0Neuron<\/i>,\u00a0105<\/i>(1), 46\u201359.e3.\u00a0https:\/\/doi.org\/10.1016\/j.neuron.2019.09.044<\/a><\/div><\/li>\r\n \t
  14. \r\n
    Moran, S. P., Xiang, Z., Doyle, C. A., Maksymetz, J., Lv, X., Faltin, S., Fisher, N. M., Niswender, C. M., Rook, J. M., Lindsley, C. W., & Conn, P. J. (2019). Biased M1 receptor-positive allosteric modulators reveal role of phospholipase D in M1-dependent rodent cortical plasticity.\u00a0Science signaling<\/i>,\u00a012<\/i>(610), eaax2057.\u00a0https:\/\/doi.org\/10.1126\/scisignal.aax2057<\/a><\/div><\/li>\r\n \t
  15. \r\n
    Sun, W., Li, J., Cui, S., Luo, L., Huang, P., Tang, C., & An, L. (2019). Sleep Deprivation Disrupts Acquisition of Contextual Fear Extinction by Affecting Circadian Oscillation of Hippocampal-Infralimbic proBDNF.\u00a0eNeuro<\/i>,\u00a06<\/i>(5), ENEURO.0165-19.2019.\u00a0https:\/\/doi.org\/10.1523\/ENEURO.0165-19.2019<\/a><\/div><\/li>\r\n \t
  16. \r\n
    Maksymetz, J., Joffe, M. E., Moran, S. P., Stansley, B. J., Li, B., Temple, K., Engers, D. W., Lawrence, J. J., Lindsley, C. W., & Conn, P. J. (2019). M1 Muscarinic Receptors Modulate Fear-Related Inputs to the Prefrontal Cortex: Implications for Novel Treatments of Posttraumatic Stress Disorder.\u00a0Biological psychiatry<\/i>,\u00a085<\/i>(12), 989\u20131000.\u00a0https:\/\/doi.org\/10.1016\/j.biopsych.2019.02.020<\/a><\/div><\/li>\r\n \t
  17. \r\n
    Joffe, M. E., Santiago, C. I., Engers, J. L., Lindsley, C. W., & Conn, P. J. (2019). Metabotropic glutamate receptor subtype 3 gates acute stress-induced dysregulation of amygdalo-cortical function.\u00a0Molecular psychiatry<\/i>,\u00a024<\/i>(6), 916\u2013927.\u00a0https:\/\/doi.org\/10.1038\/s41380-017-0015-z<\/a><\/div><\/li>\r\n \t
  18. \r\n
    Stansley, B. J., & Conn, P. J. (2019). Neuropharmacological Insight from Allosteric Modulation of mGlu Receptors.\u00a0Trends in pharmacological sciences<\/i>,\u00a040<\/i>(4), 240\u2013252.\u00a0https:\/\/doi.org\/10.1016\/j.tips.2019.02.006<\/a><\/div><\/li>\r\n \t
  19. \r\n
    Neale, J. H., & Olszewski, R. (2019). A role for N-acetylaspartylglutamate (NAAG) and mGluR3 in cognition.\u00a0Neurobiology of learning and memory<\/i>,\u00a0158<\/i>, 9\u201313.\u00a0https:\/\/doi.org\/10.1016\/j.nlm.2019.01.006<\/a><\/div><\/li>\r\n \t
  20. \r\n
    Joffe, M. E., Santiago, C. I., Stansley, B. J., Maksymetz, J., Gogliotti, R. G., Engers, J. L., Nicoletti, F., Lindsley, C. W., & Conn, P. J. (2019). Mechanisms underlying prelimbic prefrontal cortex mGlu3\/mGlu5-dependent plasticity and reversal learning deficits following acute stress.\u00a0Neuropharmacology<\/i>,\u00a0144<\/i>, 19\u201328.\u00a0https:\/\/doi.org\/10.1016\/j.neuropharm.2018.10.013<\/a><\/div><\/li>\r\n \t
  21. \r\n
    de la Fuente Revenga, M., Ibi, D., Cuddy, T., Toneatti, R., Kurita, M., Ijaz, M. K., Miles, M. F., Wolstenholme, J. T., & Gonz\u00e1lez-Maeso, J. (2019). Chronic clozapine treatment restrains via HDAC2 the performance of mGlu2 receptor agonism in a rodent model of antipsychotic activity.\u00a0Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology<\/i>,\u00a044<\/i>(2), 443\u2013454.\u00a0https:\/\/doi.org\/10.1038\/s41386-018-0143-4<\/a><\/div><\/li>\r\n \t
  22. \r\n
    Mazzitelli, M., Palazzo, E., Maione, S., & Neugebauer, V. (2018). Group II Metabotropic Glutamate Receptors: Role in Pain Mechanisms and Pain Modulation.\u00a0Frontiers in molecular neuroscience<\/i>,\u00a011<\/i>, 383.\u00a0https:\/\/doi.org\/10.3389\/fnmol.2018.00383<\/a><\/div><\/li>\r\n \t
  23. \r\n
    Joffe, M. E., Centanni, S. W., Jaramillo, A. A., Winder, D. G., & Conn, P. J. (2018). Metabotropic Glutamate Receptors in Alcohol Use Disorder: Physiology, Plasticity, and Promising Pharmacotherapies.\u00a0ACS chemical neuroscience<\/i>,\u00a09<\/i>(9), 2188\u20132204.\u00a0https:\/\/doi.org\/10.1021\/acschemneuro.8b00200<\/a><\/div><\/li>\r\n \t
  24. \r\n
    Hsu, T. M., Noble, E. E., Liu, C. M., Cortella, A. M., Konanur, V. R., Suarez, A. N., Reiner, D. J., Hahn, J. D., Hayes, M. R., & Kanoski, S. E. (2018). A hippocampus to prefrontal cortex neural pathway inhibits food motivation through glucagon-like peptide-1 signaling.\u00a0Molecular psychiatry<\/i>,\u00a023<\/i>(7), 1555\u20131565.\u00a0https:\/\/doi.org\/10.1038\/mp.2017.91<\/a><\/div><\/li>\r\n \t
  25. \r\n
    O’Brien, D. E., Shaw, D. M., Cho, H. P., Cross, A. J., Wesolowski, S. S., Felts, A. S., Bergare, J., Elmore, C. S., Lindsley, C. W., Niswender, C. M., & Conn, P. J. (2018). Differential Pharmacology and Binding of mGlu2 Receptor Allosteric Modulators.\u00a0Molecular pharmacology<\/i>,\u00a093<\/i>(5), 526\u2013540.\u00a0https:\/\/doi.org\/10.1124\/mol.117.110114<\/a><\/div><\/li>\r\n \t
  26. \r\n
    Ting, J. T., Lee, B. R., Chong, P., Soler-Llavina, G., Cobbs, C., Koch, C., Zeng, H., & Lein, E. (2018). Preparation of Acute Brain Slices Using an Optimized N-Methyl-D-glucamine Protective Recovery Method.\u00a0Journal of visualized experiments : JoVE<\/i>, (132), 53825.\u00a0https:\/\/doi.org\/10.3791\/53825<\/a><\/div><\/li>\r\n \t
  27. \r\n
    Ershov, N. I., Bondar, N. P., Lepeshko, A. A., Reshetnikov, V. V., Ryabushkina, J. A., & Merkulova, T. I. (2018). Consequences of early life stress on genomic landscape of H3K4me3 in prefrontal cortex of adult mice.\u00a0BMC genomics<\/i>,\u00a019<\/i>(Suppl 3), 93.\u00a0https:\/\/doi.org\/10.1186\/s12864-018-4479-2<\/a><\/div><\/li>\r\n \t
  28. \r\n
    Stansley, B. J., & Conn, P. J. (2018). The therapeutic potential of metabotropic glutamate receptor modulation for schizophrenia.\u00a0Current opinion in pharmacology<\/i>,\u00a038<\/i>, 31\u201336.\u00a0https:\/\/doi.org\/10.1016\/j.coph.2018.02.003<\/a><\/div><\/li>\r\n \t
  29. \r\n
    Di Menna, L., Joffe, M. E., Iacovelli, L., Orlando, R., Lindsley, C. W., Mairesse, J., Gress\u00e8ns, P., Cannella, M., Caraci, F., Copani, A., Bruno, V., Battaglia, G., Conn, P. J., & Nicoletti, F. (2018). Functional partnership between mGlu3 and mGlu5 metabotropic glutamate receptors in the central nervous system.\u00a0Neuropharmacology<\/i>,\u00a0128<\/i>, 301\u2013313.\u00a0https:\/\/doi.org\/10.1016\/j.neuropharm.2017.10.026<\/a><\/div><\/li>\r\n \t
  30. \r\n
    Walker, A. G., Sheffler, D. J., Lewis, A. S., Dickerson, J. W., Foster, D. J., Senter, R. K., Moehle, M. S., Lv, X., Stansley, B. J., Xiang, Z., Rook, J. M., Emmitte, K. A., Lindsley, C. W., & Conn, P. J. (2017). Co-Activation of Metabotropic Glutamate Receptor 3 and Beta-Adrenergic Receptors Modulates Cyclic-AMP and Long-Term Potentiation, and Disrupts Memory Reconsolidation.\u00a0Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology<\/i>,\u00a042<\/i>(13), 2553\u20132566.\u00a0https:\/\/doi.org\/10.1038\/npp.2017.136<\/a><\/div><\/li>\r\n \t
  31. \r\n
    Engers, J. L., Bollinger, K. A., Weiner, R. L., Rodriguez, A. L., Long, M. F., Breiner, M. M., Chang, S., Bollinger, S. R., Bubser, M., Jones, C. K., Morrison, R. D., Bridges, T. M., Blobaum, A. L., Niswender, C. M., Conn, P. J., Emmitte, K. A., & Lindsley, C. W. (2017). Design and Synthesis of\u00a0N<\/i>-Aryl Phenoxyethoxy Pyridinones as Highly Selective and CNS Penetrant mGlu3 NAMs.\u00a0ACS medicinal chemistry letters<\/i>,\u00a08<\/i>(9), 925\u2013930.\u00a0https:\/\/doi.org\/10.1021\/acsmedchemlett.7b00249<\/a><\/div><\/li>\r\n \t
  32. \r\n
    Bollinger, K. A., Felts, A. S., Brassard, C. J., Engers, J. L., Rodriguez, A. L., Weiner, R. L., Cho, H. P., Chang, S., Bubser, M., Jones, C. K., Blobaum, A. L., Niswender, C. M., Conn, P. J., Emmitte, K. A., & Lindsley, C. W. (2017). Design and Synthesis of mGlu2 NAMs with Improved Potency and CNS Penetration Based on a Truncated Picolinamide Core.\u00a0ACS medicinal chemistry letters<\/i>,\u00a08<\/i>(9), 919\u2013924.\u00a0https:\/\/doi.org\/10.1021\/acsmedchemlett.7b00279<\/a><\/div><\/li>\r\n \t
  33. \r\n
    McColm, J., Brittain, C., Suriyapperuma, S., Swanson, S., Tauscher-Wisniewski, S., Foster, J., Soon, D., & Jackson, K. (2017). Evaluation of single and multiple doses of a novel mGlu2 agonist, a potential antipsychotic therapy, in healthy subjects.\u00a0British journal of clinical pharmacology<\/i>,\u00a083<\/i>(8), 1654\u20131667.\u00a0https:\/\/doi.org\/10.1111\/bcp.13252<\/a><\/div><\/li>\r\n \t
  34. \r\n
    Foster, D. J., & Conn, P. J. (2017). Allosteric Modulation of GPCRs: New Insights and Potential Utility for Treatment of Schizophrenia and Other CNS Disorders.\u00a0Neuron<\/i>,\u00a094<\/i>(3), 431\u2013446.\u00a0https:\/\/doi.org\/10.1016\/j.neuron.2017.03.016<\/a><\/div><\/li>\r\n \t
  35. \r\n
    Johnson, K. A., Mateo, Y., & Lovinger, D. M. (2017). Metabotropic glutamate receptor 2 inhibits thalamically-driven glutamate and dopamine release in the dorsal striatum.\u00a0Neuropharmacology<\/i>,\u00a0117<\/i>, 114\u2013123.\u00a0https:\/\/doi.org\/10.1016\/j.neuropharm.2017.01.038<\/a><\/div><\/li>\r\n \t
  36. \r\n
    Le Hellard, S., Wang, Y., Witoelar, A., Zuber, V., Bettella, F., Hugdahl, K., Espeseth, T., Steen, V. M., Melle, I., Desikan, R., Schork, A. J., Thompson, W. K., Dale, A. M., Djurovic, S., Andreassen, O. A., & Schizophrenia Working Group of the Psychiatric Genomics Consortium (2017). Identification of Gene Loci That Overlap Between Schizophrenia and Educational Attainment.\u00a0Schizophrenia bulletin<\/i>,\u00a043<\/i>(3), 654\u2013664.\u00a0https:\/\/doi.org\/10.1093\/schbul\/sbw085<\/a><\/div><\/li>\r\n \t
  37. \r\n
    Maksymetz, J., Moran, S. P., & Conn, P. J. (2017). Targeting metabotropic glutamate receptors for novel treatments of schizophrenia.\u00a0Molecular brain<\/i>,\u00a010<\/i>(1), 15.\u00a0https:\/\/doi.org\/10.1186\/s13041-017-0293-z<\/a><\/div><\/li>\r\n \t
  38. \r\n
    Liu, W., Ge, T., Leng, Y., Pan, Z., Fan, J., Yang, W., & Cui, R. (2017). The Role of Neural Plasticity in Depression: From Hippocampus to Prefrontal Cortex.\u00a0Neural plasticity<\/i>,\u00a02017<\/i>, 6871089.\u00a0https:\/\/doi.org\/10.1155\/2017\/6871089<\/a><\/div><\/li>\r\n \t
  39. \r\n
    Johnson, K. A., & Lovinger, D. M. (2016). Presynaptic G Protein-Coupled Receptors: Gatekeepers of Addiction?.\u00a0Frontiers in cellular neuroscience<\/i>,\u00a010<\/i>, 264.\u00a0https:\/\/doi.org\/10.3389\/fncel.2016.00264<\/a><\/div><\/li>\r\n \t
  40. \r\n
    Kang, S. J., & Kaang, B. K. (2016). Metabotropic glutamate receptor dependent long-term depression in the cortex.\u00a0The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology<\/i>,\u00a020<\/i>(6), 557\u2013564.\u00a0https:\/\/doi.org\/10.4196\/kjpp.2016.20.6.557<\/a><\/div><\/li>\r\n \t
  41. \r\n
    Samarasinghe, K. T., Munkanatta Godage, D. N., Zhou, Y., Ndombera, F. T., Weerapana, E., & Ahn, Y. H. (2016). A clickable glutathione approach for identification of protein glutathionylation in response to glucose metabolism.\u00a0Molecular bioSystems<\/i>,\u00a012<\/i>(8), 2471\u20132480.\u00a0https:\/\/doi.org\/10.1039\/c6mb00175k<\/a><\/div><\/li>\r\n \t
  42. \r\n
    Lindsley, C. W., Emmitte, K. A., Hopkins, C. R., Bridges, T. M., Gregory, K. J., Niswender, C. M., & Conn, P. J. (2016). Practical Strategies and Concepts in GPCR Allosteric Modulator Discovery: Recent Advances with Metabotropic Glutamate Receptors.\u00a0Chemical reviews<\/i>,\u00a0116<\/i>(11), 6707\u20136741.\u00a0https:\/\/doi.org\/10.1021\/acs.chemrev.5b00656<\/a><\/div><\/li>\r\n \t
  43. \r\n
    Muguruza, C., Meana, J. J., & Callado, L. F. (2016). Group II Metabotropic Glutamate Receptors as Targets for Novel Antipsychotic Drugs.\u00a0Frontiers in pharmacology<\/i>,\u00a07<\/i>, 130.\u00a0https:\/\/doi.org\/10.3389\/fphar.2016.00130<\/a><\/div><\/li>\r\n \t
  44. \r\n
    O’Brien, D. E., & Conn, P. J. (2016). Neurobiological Insights from mGlu Receptor Allosteric Modulation.\u00a0The international journal of neuropsychopharmacology<\/i>,\u00a019<\/i>(5), pyv133.\u00a0https:\/\/doi.org\/10.1093\/ijnp\/pyv133<\/a><\/div><\/li>\r\n \t
  45. \r\n
    Senter, R. K., Ghoshal, A., Walker, A. G., Xiang, Z., Niswender, C. M., & Conn, P. J. (2016). The Role of mGlu Receptors in Hippocampal Plasticity Deficits in Neurological and Psychiatric Disorders: Implications for Allosteric Modulators as Novel Therapeutic Strategies.\u00a0Current neuropharmacology<\/i>,\u00a014<\/i>(5), 455\u2013473.\u00a0https:\/\/doi.org\/10.2174\/1570159×13666150421003225<\/a><\/div><\/li>\r\n \t
  46. \r\n
    Balu D. T. (2016). The NMDA Receptor and Schizophrenia: From Pathophysiology to Treatment.\u00a0Advances in pharmacology (San Diego, Calif.)<\/i>,\u00a076<\/i>, 351\u2013382.\u00a0https:\/\/doi.org\/10.1016\/bs.apha.2016.01.006<\/a><\/div><\/li>\r\n \t
  47. \r\n
    Ghoshal, A., Rook, J. M., Dickerson, J. W., Roop, G. N., Morrison, R. D., Jalan-Sakrikar, N., Lamsal, A., Noetzel, M. J., Poslusney, M. S., Wood, M. R., Melancon, B. J., Stauffer, S. R., Xiang, Z., Daniels, J. S., Niswender, C. M., Jones, C. K., Lindsley, C. W., & Conn, P. J. (2016). Potentiation of M1 Muscarinic Receptor Reverses Plasticity Deficits and Negative and Cognitive Symptoms in a Schizophrenia Mouse Model.\u00a0Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology<\/i>,\u00a041<\/i>(2), 598\u2013610.\u00a0https:\/\/doi.org\/10.1038\/npp.2015.189<\/a><\/div><\/li>\r\n \t
  48. \r\n
    Felts, A. S., Rodriguez, A. L., Smith, K. A., Engers, J. L., Morrison, R. D., Byers, F. W., Blobaum, A. L., Locuson, C. W., Chang, S., Venable, D. F., Niswender, C. M., Daniels, J. S., Conn, P. J., Lindsley, C. W., & Emmitte, K. A. (2015). Design of 4-Oxo-1-aryl-1,4-dihydroquinoline-3-carboxamides as Selective Negative Allosteric Modulators of Metabotropic Glutamate Receptor Subtype 2.\u00a0Journal of medicinal chemistry<\/i>,\u00a058<\/i>(22), 9027\u20139040.\u00a0https:\/\/doi.org\/10.1021\/acs.jmedchem.5b01371<\/a><\/div><\/li>\r\n \t
  49. \r\n
    Engers, J. L., Rodriguez, A. L., Konkol, L. C., Morrison, R. D., Thompson, A. D., Byers, F. W., Blobaum, A. L., Chang, S., Venable, D. F., Loch, M. T., Niswender, C. M., Daniels, J. S., Jones, C. K., Conn, P. J., Lindsley, C. W., & Emmitte, K. A. (2015). Discovery of a Selective and CNS Penetrant Negative Allosteric Modulator of Metabotropic Glutamate Receptor Subtype 3 with Antidepressant and Anxiolytic Activity in Rodents.\u00a0Journal of medicinal chemistry<\/i>,\u00a058<\/i>(18), 7485\u20137500.\u00a0https:\/\/doi.org\/10.1021\/acs.jmedchem.5b01005<\/a><\/div><\/li>\r\n \t
  50. \r\n
    Kiritoshi, T., & Neugebauer, V. (2015). Group II mGluRs modulate baseline and arthritis pain-related synaptic transmission in the rat medial prefrontal cortex.\u00a0Neuropharmacology<\/i>,\u00a095<\/i>, 388\u2013394.\u00a0https:\/\/doi.org\/10.1016\/j.neuropharm.2015.04.003<\/a><\/div><\/li>\r\n \t
  51. \r\n
    Ellaithy, A., Younkin, J., Gonz\u00e1lez-Maeso, J., & Logothetis, D. E. (2015). Positive allosteric modulators of metabotropic glutamate 2 receptors in schizophrenia treatment.\u00a0Trends in neurosciences<\/i>,\u00a038<\/i>(8), 506\u2013516.\u00a0https:\/\/doi.org\/10.1016\/j.tins.2015.06.002<\/a><\/div><\/li>\r\n<\/ol>\r\n<\/div>","protected":false},"excerpt":{"rendered":"Abstract Clinical studies have revealed that genetic variations in metabotropic glutamate receptor 3 (mGlu3) affect performance on cognitive tasks dependent upon the prefrontal cortex (PFC) and may be linked to psychiatric conditions such as schizophrenia, …","protected":false},"author":7,"featured_media":194,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[3],"tags":[],"class_list":["post-193","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-feature-publications"],"acf":[],"_links":{"self":[{"href":"https:\/\/pharmacy.wisc.edu\/faculty\/wenthur-lab\/wp-json\/wp\/v2\/posts\/193","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharmacy.wisc.edu\/faculty\/wenthur-lab\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharmacy.wisc.edu\/faculty\/wenthur-lab\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharmacy.wisc.edu\/faculty\/wenthur-lab\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/pharmacy.wisc.edu\/faculty\/wenthur-lab\/wp-json\/wp\/v2\/comments?post=193"}],"version-history":[{"count":1,"href":"https:\/\/pharmacy.wisc.edu\/faculty\/wenthur-lab\/wp-json\/wp\/v2\/posts\/193\/revisions"}],"predecessor-version":[{"id":195,"href":"https:\/\/pharmacy.wisc.edu\/faculty\/wenthur-lab\/wp-json\/wp\/v2\/posts\/193\/revisions\/195"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pharmacy.wisc.edu\/faculty\/wenthur-lab\/wp-json\/wp\/v2\/media\/194"}],"wp:attachment":[{"href":"https:\/\/pharmacy.wisc.edu\/faculty\/wenthur-lab\/wp-json\/wp\/v2\/media?parent=193"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharmacy.wisc.edu\/faculty\/wenthur-lab\/wp-json\/wp\/v2\/categories?post=193"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharmacy.wisc.edu\/faculty\/wenthur-lab\/wp-json\/wp\/v2\/tags?post=193"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}